Merck Chief Executive Officer Robert Davis's total compensation decreased by 10% in 2025, amounting to $20.8 million according to a Securities and Exchange Commission filing released on April 8, 2026. This reduction from the previous year's total of $23.2 million was primarily driven by declines in his stock and option awards rather than changes in base salary. Specifically, Davis's stock awards dropped by approximately $1 million to reach $12.1 million, while his option awards fell by about $1.3 million to settle at $3.4 million. His non-equity incentive compensation also saw a slight decline of less than half a million dollars during the reporting period. In contrast to the significant drops in equity-based pay, Davis's base salary for 2025 increased from $1.62 million in 2024 to $1.65 million, representing a small but notable annual adjustment. The decrease in total compensation was largely attributed to lower stock prices and reduced value of option awards at the time they were settled or granted, factors that often fluctuate based on market conditions for Merck's equity. Despite the overall drop in executive pay linked to equity performance, the company noted that Davis's fixed salary component continued to rise slightly. The report also highlighted compensation details for other senior leadership, noting that Chief Financial Officer Caroline Litchfield maintained a flat total compensation package at roughly $7.5 million in 2025 compared to the prior year. While specific numbers for her equity components were not detailed in this summary of CEO-focused filings, her overall pay remained stable against the backdrop of Merck's broader executive compensation adjustments. The data reflects market-driven fluctuations impacting variable pay structures rather than uniform cuts across all components of executive remuneration.